Search
forLearn
5 / 801 resultslearn Dextran
learn Desoximetasone
learn multipeptides
learn enoxolone
Research
5 / 1000+ results
research Pro‐Regenerative Hydrogel Restores Scarless Skin during Cutaneous Wound Healing
A special hydrogel helps heal skin without scars and regrows hair.
research Engineering Pro‐Regenerative Hydrogels for Scarless Wound Healing
Hydrogels could lead to better treatments for wound healing without scars.
research Relative Safety and Efficacy of Finasteride for Treatment of Hirsutism
Finasteride reduces hirsutism effectively with fewer side effects but is a second-choice treatment due to safety concerns.
research Oral Contraceptives as Anti-Androgenic Treatment of Acne
Birth control pills can help reduce mild to moderate acne in women.
research Hyperandrogénie féminine
The document concludes that managing female hyperandrogenism requires a combination of identifying the cause, lifestyle changes, medication, and cosmetic treatments.
Community Join
5 / 1000+ resultscommunity Second shed is real guys !!!!!
The conversation discusses hair shedding experienced by users on minoxidil and finasteride treatments, with some considering additional options like spironolactone and dutasteride. Many users report experiencing a second shedding phase but are advised to continue treatment as it may lead to thicker hair regrowth.
community Veradermics VDPHL01 Topline Results for Extended-Release Oral Minoxidil
Veradermics is working on FDA approval for extended-release oral Minoxidil. Approval is expected around 2027.
community Following the recent IPO and the positive Phase 3 clinical data for VDPHL01 (extended-release oral minoxidil), what is the projected timeline for the FDA submission and the subsequent commercial availability on the market?
Veradermics' extended-release oral minoxidil is expected to be commercially available in 2027-2028, while another company, Minx, may release a similar product sooner. VDPHL01 is considered more clinically validated compared to Minx.
community Veradermics VDPHL01 Topline Results for Extended-Release Oral Minoxidil
Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.
community 6 months Minodixil 5mg/Dutasteride 0.5mg
A 25-year-old uses oral minoxidil, dutasteride, and a shampoo with minoxidil and ketoconazole for hair loss, experiencing progress and increased body hair. Users discuss the effectiveness of these treatments, with some suggesting that dutasteride is primarily responsible for hair thickening.